NeurOp, Inc. has received $346,000 from the National Institutes of Health (NIH), the second half of a $700,000 grant made last year to support its schizophrenia treatment research. NeurOp is studying NR2C and NR2D subunit-selective NMDA receptor compounds as potential new antipsychotic medications.

“This grant required that we meet certain research objectives to qualify for the second year of funding, and I’m pleased to say that we accomplished those,” said Barney Koszalka, Ph.D., NeurOp president and chief executive officer. “In the next 12 months, our goal is to use these funds to advance the medicinal chemistry and pharmacology work that are needed to complete a proof of concept in animals.”

This project is supported by the National Institute of Mental Health of the National Institutes of Health under award number R43MH096363. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Schizophrenia

Schizophrenia is a complex, disabling and chronic brain disorder that typically strikes in the early adult years and affects one percent of the world’s population. According to the National Institute of Mental Health, people with the disorder may hear voices that others do not. They may also believe other people are reading their minds, controlling their thoughts, or plotting to harm them. This can terrify people with the illness and make them withdrawn or extremely agitated. Symptoms such as hallucinations and delusions usually start between ages 16 and 30.

Because the causes of schizophrenia are unknown, treatments focus on eliminating the symptoms and include antipsychotic medications, designated as typical and atypical, and various psychosocial treatments.

About NeurOp

NeurOp, Inc. is an Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including depression, neuropathic pain, ischemia (stroke), schizophrenia, and Alzheimer’s and Parkinson’s diseases. Its research targets various subunits of neuronal NMDA receptors and their potential therapeutic benefit. A research collaboration and licensing agreement with Bristol-Myers Squibb currently funds and supports development of NeurOp’s compounds for the treatment of depression and neuropathic pain. Multi-year funding from the NIH supports its ischemia and schizophrenia research. For more information, please visit

NeurOp contact:

Barney Koszalka, CEO
Phone: 404.941.2350